Amgen (AMGN) Q4 Preview: Key Insights Before Earnings Release

Amgen Set to Announce Earnings: What Investors Should Know

Amgen (NASDAQ:AMGN), a leading biotechnology firm, is scheduled to release its earnings report this Tuesday after market close. Here’s a breakdown of what to expect.

In the previous quarter, Amgen delivered impressive results, surpassing revenue forecasts by 6.6%. The company posted $9.56 billion in revenue, marking a 12.4% increase compared to the same period last year. Not only did Amgen outperform analyst expectations, but its full-year revenue outlook also exceeded Wall Street’s projections.

Should You Buy or Sell Amgen Before Earnings?

Curious about Amgen’s investment potential ahead of its earnings release?

Analyst Expectations for This Quarter

For the upcoming quarter, analysts anticipate Amgen’s revenue will reach $9.47 billion, reflecting a 4.3% year-over-year increase. This growth rate is slower than the 10.9% rise reported in the same quarter last year. Adjusted earnings per share are projected to be $4.76.

Amgen Total Revenue

Over the past month, most analysts have maintained their forecasts for Amgen, indicating confidence in the company’s performance as earnings approach. Amgen has a strong track record, having only missed revenue estimates once in the last two years and typically exceeding expectations by an average of 1.9%.

Industry Comparison: How Peers Are Performing

Among Amgen’s biotechnology peers, Regeneron is the only company to have reported results so far. Regeneron surpassed revenue estimates by 2.7% and achieved 2.5% year-over-year sales growth.

For a detailed look at Regeneron’s earnings performance.

Biotech Sector and Amgen’s Stock Performance

Biotechnology stocks have remained stable in the lead-up to earnings, with share prices holding steady over the past month. In contrast, Amgen’s stock has risen 6.7% during this period. The average analyst price target for Amgen stands at $332.70, while the current share price is $341.35.

Spotlight: Share Buybacks and a Special Opportunity

When companies accumulate excess cash, repurchasing their own shares can be a smart move—provided the valuation is attractive. We’ve identified a promising, undervalued stock that’s generating substantial free cash flow and actively buying back shares.